Last reviewed · How we verify
Aripiprazole IM Depot
At a glance
| Generic name | Aripiprazole IM Depot |
|---|---|
| Also known as | OPC-14597, Lu AF41155, Oral Aripiprazole, Aripiprazole Intramuscular Depot, Abilify |
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Weight Increased
- Nasopharyngitis
- Headache
- Insomnia
- Upper Respiratory Tract Infection
- Anxiety
- Influenza
- Back Pain
- Diarrhoea
- Injection Site Pain
- Akathisia
- Constipation
Key clinical trials
- A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder (PHASE1, PHASE2)
- A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia (PHASE1)
- Aripiprazole IM Depot for Chinese Patients With Schizophrenia (PHASE1)
- Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia (PHASE3)
- European Long-acting Antipsychotics in Schizophrenia Trial (PHASE4)
- PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia (PHASE1)
- An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia (PHASE3)
- Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |